Matthew Maenner is surveillance team lead for the National Center on Birth Defects and Developmental Disabilities at the U.S. Centers for Disease Control and Prevention.
Matthew Maenner
Surveillance team lead
National Center on Birth Defects and Developmental Disabilities
From this contributor
Q&A with Matthew Maenner: Estimating autism prevalence quickly
A new method to track autism prevalence in 11 U.S. states is twice as fast as the old approach — and yields similar results.
Q&A with Matthew Maenner: Estimating autism prevalence quickly
Explore more from The Transmitter
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
When autistic kids grow up, Chapter 1: Those people
What leads an autism researcher to publish an intentionally inflammatory paper accusing the NIH of discrimination?
When autistic kids grow up, Chapter 1: Those people
What leads an autism researcher to publish an intentionally inflammatory paper accusing the NIH of discrimination?
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.